Human FGF‐1 gene transfer promotes the formation of collateral vessels and arterioles in ischemic muscles of hypercholesterolemic hamsters
- 26 April 2004
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 6 (9) , 1033-1045
- https://doi.org/10.1002/jgm.594
Abstract
Background Acidic fibroblast growth factor (FGF-1) has been identified as a potent mitogen for vascular cells, inducing formation of mature blood vessels in vitro and in vivo and represents one of the most promising approaches for the treatment of ischemic cardiovascular diseases by gene therapy. Nevertheless, and most probably due to the few experimental models able to address the issue, no study has described the therapeutic effects of FGF-1 gene transfer in subjects with peripheral arterial disease (PAD) exhibiting a clinically relevant cardiovascular pathology. Methods In order to assess the potency of FGF-1 gene transfer for therapeutic angiogenesis in ischemic skeletal muscles displaying decreased gene expression levels and sustained impaired formation of collateral vessels and arterioles, we developed a model of PAD in hamsters with a background of hypercholesterolemia. Hamsters fed a cholesterol-rich diet and subjected to hindlimb ischemia exhibit a sustained impaired angiogenic response, as evidenced by decreased angiographic score and histological quantification of arterioles in the ischemic muscles. Results In this model, we demonstrate that NV1FGF (a human FGF-1 expression plasmid), given intramuscularly 14 days after induction of hindlimb ischemia, promoted the formation of both collateral vessels and arterioles 14 days after treatment (i.e. 28 days post-ischemia). Conclusions Our data provide evidence that NV1FGF can reverse the cholesterol-induced impairment of revascularization in a hamster model of hindlimb ischemia by promoting the growth of both collateral vessels and arterioles in ischemic muscles exhibiting significantly decreased levels of gene expression compared with control muscles. Therefore, this study underscores the relevance of NV1FGF gene therapy to overcome perfusion defects in patients with PAD. Copyright © 2004 John Wiley & Sons, Ltd.Keywords
This publication has 34 references indexed in Scilit:
- Therapeutic angiogenesis: a step forward in intermittent claudicationThe Lancet, 2002
- Peripheral arterial diseaseThe Lancet, 2001
- Endothelial dysfunction in type 2 diabetes mellitus subjects with peripheral artery diseaseInternational Journal of Cardiology, 2001
- AtherosclerosisNature, 2000
- FGF signals for cell proliferation and migration through different pathwaysCytokine & Growth Factor Reviews, 2000
- Clinical applications of angiogenic growth factors and their inhibitorsNature Medicine, 1999
- Lipids and the endotheliumCardiovascular Research, 1999
- Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in use of naked DNA.Cardiovascular Research, 1997
- Therapeutic angiogenesis: A comparative study of the angiogenic potential of acidic fibroblast growth factor and heparinJournal of Vascular Surgery, 1997
- Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivoNature, 1993